United States Judicial Panel on Multidistrict Litigation February 7, 2017, MDL No. 2754 (In re Eliquis (Apixaban) Prods. Liab. Litig.)

SARAH S. VANCE, Chair

Before the Panel : Defendants Bristol-Myers Squibb Company (BMS) and Pfizer Inc. move under 28 U.S.C. § 1407 to centralize this litigation in the Southern District of New York. This litigation currently consists of 34 actions pending in 13 districts, as listed on Schedule A. Since the filing of the motion, the Panel has been notified of 19 related federal actions.